Just a moment, the page is loading...
Browse ALL STUDIES
Keyword Search
View All Selected
Clear All
Login / Create Account
Login
Create Account
Home
About Us
Privacy Policy
Minimum System Requirements
How To Join
Mission
Data Sponsors
Researchers
How It Works
How to Request Data
Review of Requests
Data Sharing Agreement
Access to Data
Independent Review Panel
Metrics
FAQs
News
Help/Contact Us
Novel approaches for the analysis of SLE clinical trials
Proposal
5525
Title of Proposed Research
Novel approaches for the analysis of SLE clinical trials
Lead Researcher
Mimi Kim
Affiliation
Albert Einstein College of Medicine
Funding Source
Potential Conflicts of Interest
Data Sharing Agreement Date
13 August 2018
Lay Summary
Lupus is a chronic autoimmune disease that is difficult to treat because the type and severity of symptoms that occur may vary considerably between patients and also within patients over time. Safer and more effective medications for lupus are urgently needed, but the fluctuating nature of the symptoms makes it very challenging for clinical trials to prove that experimental treatments are superior to standard therapies. As a result, many lupus trials in the past have failed, and it is often unclear whether this failure is due to the drug not working or because the study designs, outcome measures, and methods for analyzing the data were not able to detect the treatment signals in the midst of considerable disease heterogeneity and other sources of background “noise”. The primary objective of this project is to use existing data from completed randomized SLE trials to obtain a greater understanding of the impact of disease heterogeneity on trial results, and to devise better methodological strategies for addressing this issue in future studies. We will apply various statistical methods to investigate the magnitude of between- and within-patient variability in treatment response patterns, and evaluate if clinical and laboratory patient characteristics, such as exposure to specific standard of care therapies, predict the likelihood and duration of response. We will also explore novel methods that make more efficient use of clinical trial data in evaluating treatment effects. Our expectation is that more stringent endpoints and analytic approaches that maximize information about a patient's disease activity during follow up will better discriminate experimental treatments from control treatments. The long-term goal in accomplishing our study aims is to substantially improve the methodological aspects of lupus trials and ultimately accelerate the discovery and approval of effective new therapies.
Study Data Provided
[{ "PostingID": 1416, "Title": "GSK-HGS1006-C1056", "Description": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE)" },{ "PostingID": 1417, "Title": "GSK-HGS1006-C1057", "Description": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)" }]
Statistical Analysis Plan
Publication Citation
© 2023 ideaPoint. All Rights Reserved.
Powered by ideaPoint.
Help
Privacy Policy
Cookie Policy
Help and Resources